Munich Reinsurance Co Stock Corp in Munich Acquires Shares of 196,537 Elevance Health, Inc. $ELV

Munich Reinsurance Co Stock Corp in Munich acquired a new position in Elevance Health, Inc. (NYSE:ELV) in the third quarter, Holdings Channel reports. The institutional investor acquired 196,537 shares of the company’s stock, valued at approximately $63,505,000. Elevance Health makes up approximately 1.6% of Munich Reinsurance Co Stock Corp in Munich’s portfolio, making the stock its 20th largest position.

Other hedge funds have also recently made changes to their positions in the company. Nilsine Partners LLC lifted its holdings in shares of Elevance Health by 1.5% in the 3rd quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after acquiring an additional 29 shares during the last quarter. HBK Sorce Advisory LLC increased its stake in Elevance Health by 4.4% during the third quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock worth $260,000 after acquiring an additional 31 shares during the last quarter. Detalus Advisors LLC increased its stake in Elevance Health by 1.8% during the third quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after acquiring an additional 31 shares during the last quarter. Forum Financial Management LP raised its position in Elevance Health by 1.1% during the third quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock valued at $960,000 after purchasing an additional 33 shares during the period. Finally, Activest Wealth Management raised its position in Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares during the period. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health Price Performance

ELV opened at $289.56 on Friday. The business has a fifty day moving average of $344.64 and a 200 day moving average of $335.01. The stock has a market cap of $63.91 billion, a P/E ratio of 11.53, a PEG ratio of 1.58 and a beta of 0.51. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business’s revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.4%. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is currently 27.23%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ELV shares. Jefferies Financial Group dropped their target price on Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a report on Friday, January 30th. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Guggenheim reduced their target price on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a research note on Thursday, January 29th. JPMorgan Chase & Co. raised their target price on shares of Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Finally, Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Twelve investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.